Literature DB >> 16759848

Establishment and characterization of xenografts and cancer cell cultures derived from BRCA1 -/- epithelial ovarian cancers.

Stefano Indraccolo1, Veronica Tisato, Simona Agata, Lidia Moserle, Silvia Ferrari, Monia Callegaro, Luca Persano, Maurizia Dalla Palma, Maria Chiara Scaini, Giovanni Esposito, Ambrogio Fassina, Ornella Nicoletto, Mario Plebani, Luigi Chieco-Bianchi, Alberto Amadori, Emma D'Andrea, Marco Montagna.   

Abstract

The BRCA1 gene is responsible for a high number of hereditary breast and ovarian cancers that cluster in families with a strong genetic predisposition. Despite intense investigation, the accumulating findings on BRCA1 biological functions have not yet been translated into specific therapeutic approaches, also due to the lack of suitable experimental models. The purpose of this study was to establish and characterize cell cultures and xenografts from patients with BRCA1 -/- ovarian cancers. We derived two ovarian cancer cell lines, termed PD-OVCA1 and PD-OVCA2, both from patients previously treated with chemotherapy, that propagate in SCID mice as well as in vitro for a limited number of passages. Both cell lines expressed cytokeratins and the CA125 tumour marker. A detailed molecular characterization highlighted both constitutive and somatic genetic events that abrogate BRCA1 gene function. Both cell lines were shown to lose the wild type BRCA1 allele; intriguingly, these deletions were apparently accompanied by gain of one or more copies of the mutant alleles. Finally, a genomic profile of major chromosomal aberrations was obtained by the Multiplex Ligation-dependent Probe Amplification (MLPA) technique, which disclosed chromosomal imbalances targeting specific genes in each cell line. The PD-OVCA1 and PD-OVCA2 ovarian cancer cell lines will provide a valuable tool for new experimental models for the study of BRCA1-associated tumour biology.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16759848     DOI: 10.1016/j.ejca.2006.01.057

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  9 in total

Review 1.  p53/NF-kB Balance in SARS-CoV-2 Infection: From OMICs, Genomics and Pharmacogenomics Insights to Tailored Therapeutic Perspectives (COVIDomics).

Authors:  Daniela Milani; Lorenzo Caruso; Enrico Zauli; Adi Mohammed Al Owaifeer; Paola Secchiero; Giorgio Zauli; Donato Gemmati; Veronica Tisato
Journal:  Front Pharmacol       Date:  2022-05-27       Impact factor: 5.988

2.  Patient-derived xenografts recapitulate molecular features of human uveal melanomas.

Authors:  Cécile Laurent; David Gentien; Sophie Piperno-Neumann; Fariba Némati; André Nicolas; Bruno Tesson; Laurence Desjardins; Pascale Mariani; Audrey Rapinat; Xavier Sastre-Garau; Jérôme Couturier; Philippe Hupé; Leanne de Koning; Thierry Dubois; Sergio Roman-Roman; Marc-Henri Stern; Emmanuel Barillot; J William Harbour; Simon Saule; Didier Decaudin
Journal:  Mol Oncol       Date:  2013-02-26       Impact factor: 6.603

3.  MTA1-mediated transcriptional repression of BRCA1 tumor suppressor gene.

Authors:  P R Molli; R R Singh; S W Lee; R Kumar
Journal:  Oncogene       Date:  2007-10-08       Impact factor: 9.867

4.  Genomic and proteomic characterization of YDOV-157, a newly established human epithelial ovarian cancer cell line.

Authors:  HanByoul Cho; Eun Suk Kang; Soon Won Hong; Youn Jin Oh; Sun Mi Choi; Sang Wun Kim; Sung Hoon Kim; Young Tae Kim; Kyoung Sun Lee; Yang Kyu Choi; Jae-Hoon Kim
Journal:  Mol Cell Biochem       Date:  2008-08-06       Impact factor: 3.396

5.  Hypoxia inducible factor-1alpha inactivation unveils a link between tumor cell metabolism and hypoxia-induced cell death.

Authors:  Elena Favaro; Giorgia Nardo; Luca Persano; Massimo Masiero; Lidia Moserle; Rita Zamarchi; Elisabetta Rossi; Giovanni Esposito; Mario Plebani; Ulrike Sattler; Thomas Mann; Wolfgang Mueller-Klieser; Vincenzo Ciminale; Alberto Amadori; Stefano Indraccolo
Journal:  Am J Pathol       Date:  2008-09-04       Impact factor: 4.307

6.  BBIT20 inhibits homologous DNA repair with disruption of the BRCA1-BARD1 interaction in breast and ovarian cancer.

Authors:  Liliana Raimundo; Angela Paterna; Juliana Calheiros; Joana Ribeiro; David S P Cardoso; Ilaria Piga; Susana Junqueira Neto; Denise Hegan; Peter M Glazer; Stefano Indraccolo; Silva Mulhovo; José Luís Costa; Maria-José U Ferreira; Lucília Saraiva
Journal:  Br J Pharmacol       Date:  2021-06-11       Impact factor: 9.473

Review 7.  Patient-derived xenograft models to improve targeted therapy in epithelial ovarian cancer treatment.

Authors:  Clare L Scott; Marc A Becker; Paul Haluska; Goli Samimi
Journal:  Front Oncol       Date:  2013-12-04       Impact factor: 6.244

8.  Resistance to glucose starvation as metabolic trait of platinum-resistant human epithelial ovarian cancer cells.

Authors:  Anna Pastò; Anna Pagotto; Giorgia Pilotto; Angela De Paoli; Gian Luca De Salvo; Alessandra Baldoni; Maria Ornella Nicoletto; Francesca Ricci; Giovanna Damia; Chiara Bellio; Stefano Indraccolo; Alberto Amadori
Journal:  Oncotarget       Date:  2017-01-24

9.  Autophagy inhibition reduces chemoresistance and tumorigenic potential of human ovarian cancer stem cells.

Authors:  Anna Pagotto; Giorgia Pilotto; Elena Laura Mazzoldi; Maria Ornella Nicoletto; Simona Frezzini; Anna Pastò; Alberto Amadori
Journal:  Cell Death Dis       Date:  2017-07-20       Impact factor: 8.469

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.